Investment
Features
FeesSafety
Academy
More
Pluang+

Novo Resources to start 2,700m drilling at Tibooburra Gold Project in late Q3 2026 targeting high-grade gold zones.

Market News
29 Jul 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Novo Resources is advancing exploration at the Tibooburra Gold Project in NSW through a joint venture with Manhattan Gold Corporation. A ~2,700 meter reverse circulation (RC) drilling program is planned to begin in late Q3 2026, focusing on the Clone and Pioneer South prospects, both known for high-grade gold mineralization. The drilling aims to extend known gold zones and test new targets identified through ongoing regional sampling and mapping. This program follows promising results from previous campaigns and is part of Novo's strategy to develop a significant gold resource in the historically under-explored Albert Goldfields area.

More News (NVO)

Novo Resources plans 2,700m drilling at Tibooburra; Pantoro, Sovereign, Titan report strong gold and mineral project progress.

Novo Resources plans 2,700m drilling at Tibooburra; Pantoro, Sovereign, Titan report strong gold and mineral project progress.

Novo Resources is set to start a 2,700-metre drilling program at its Tibooburra Gold Project in New South Wales in late September 2026, pending approvals. Pantoro Gold reported solid gold production and cost efficiency at its Norseman mine, with grow...

Company Fundamentals
Bullish
4 hours ago
Judge allows parts of lawsuit against Novo Nordisk over weight-loss drug CagriSema to proceed

Judge allows parts of lawsuit against Novo Nordisk over weight-loss drug CagriSema to proceed

A U.S. judge has allowed parts of a shareholder lawsuit against Novo Nordisk to move forward, alleging the company misled investors about the design and tolerability of its experimental weight-loss drug CagriSema. Investors claim Novo did not fully d...

Market News
Bearish
1 day ago
Novo Nordisk expands share buyback with DKK 11.2 billion repurchase through Feb 2027

Novo Nordisk expands share buyback with DKK 11.2 billion repurchase through Feb 2027

Novo Nordisk has launched a share repurchase program to buy back B shares worth up to DKK 11.2 billion from May 2026 to February 2027, as part of a larger DKK 15 billion buyback plan starting February 2026. Since February, the company has repurchased...

Company Fundamentals
Bullish
2 days ago
Novo Nordisk raises price target to $80 as oral Wegovy hits 3M prescriptions in 5 months, expanding market potential.

Novo Nordisk raises price target to $80 as oral Wegovy hits 3M prescriptions in 5 months, expanding market potential.

Novo Nordisk is rated a Modest Buy with an increased price target of $80, driven by the rapid adoption of its oral Wegovy medication. Oral Wegovy has achieved over 3 million prescriptions within five months, with 80% of users being new to GLP-1 treat...

Analyst Insights
Bullish
3 days ago
Novo Nordisk stock falls 30%+ as investors eye Q2 results and growth catalysts

Novo Nordisk stock falls 30%+ as investors eye Q2 results and growth catalysts

Novo Nordisk's stock has dropped over 30% since mid-2024 amid ongoing downtrend. Investors are focusing on the upcoming Q2 earnings report, paying close attention to management's confidence in their transformation plans rather than short-term earning...

Company Fundamentals
Bullish
3 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App